Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 3Ovarian Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasm Metastasis 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Advanced HER2+Breast Cancer 1

Interventions

Bevacizumab 12olaparib 11Paclitaxel 11Carboplatin 11liposomal doxorubicin 7Specimen Handling 7Magnetic Resonance Spectroscopy 6Taxes 5Immunoglobulin G 5Disulfides 5mirvetuximab soravtansine 4cediranib 4Topotecan 4Gemcitabine 4Biopsy 4pembrolizumab 3Oxaliplatin 2Doxorubicin 21-dodecylpyridoxal 2vistusertib 1tremelimumab 1trastuzumab deruxtecan 1sotorasib 1sarilumab 1palbociclib 1niraparib 1nilotinib 1neratinib 1irinotecan sucrosofate 1ipatasertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × Alpelisib × 30 days × Clear all
NCT05564377 2026-06-12

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
2,900 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡